Liquefaction is an independent prognostic factor for patients with osteosarcoma, but it has yet to be reported in thyroid carcinoma. This is the first published English language case report of treatment-induced tumor necrosis in metastatic-differentiated thyroid carcinoma.
thyroid tissue without evidence of malignancy. She underwent adjuvant radioactive iodine (RAI) therapy four times with 200 mCi in each cycle. However, she complained of worsening left thigh pain. Abdominal computed tomography (CT) revealed a large metastatic tumor up to 8.8 cm in size in the left L1-L4 paraspinal region [ Figure 3a ], and positron emission tomography (PET) revealed a large hypermetabolic mass [ Figure 3b ].
Her serum thyroid-stimulating hormone and thyroglobulin levels were <0.005 mIU/L and 1564.9 ng/mL, respectively, at that time. We initiated palliative radiotherapy with 30 Gy/15 Fx to the left L1-L4 paraspinal mass for symptom relief and also started low-dose sorafenib treatment (200 mg twice daily) to minimize the risk of sorafenib-related toxicity. 
dIscussIon
According to the 2015 American Thyroid Association guidelines, external-beam radiotherapy (EBRT) is indicated for locoregional control and symptoms relief in metastatic thyroid carcinoma if RAI-resistance occurs. [1] The first case report [2] about concurrent EBRT with sorafenib or doxorubicin included five patients with bulky differentiated thyroid carcinoma and demonstrated tolerable toxicity (two patients experienced G2 mucositis and two patients experienced G1 palmoplantar erythrodysesthesia) and acceptable antitumor activity (all had a partial response). The total dose of radiotherapy ranged from 50 to 64.8 Gy and four of the five patients received concurrent sorafenib. The dose of sorafenib in two patients was 400 mg twice daily and the other two received 400 mg daily. Despite a lower radiotherapy dose (total 30 Gy) and low-dose sorafenib (200 mg twice daily), our case had a similar partial response as in the previous research. In addition, this is the first case to show a significant improvement with treatment-related liquefaction.
Tumor necrosis is considered to be a consequence of several complex processes, including tumor cell apoptosis, insufficient blood supply, and tissue-lysing substances released from inflammatory cells. Three mechanisms underlying radiation-induced cell death have been proposed: apoptosis, mitotic catastrophe, and senescence. [3] Sorafenib inhibits cell proliferation by inducing cell cycle arrest and caspase activation. [4] The spectrum of multikinase inhibition of sorafenib may have a synergistic effect with radiation. [5] Tang et al. [6] observed that Raf-1 was overexpressed in radiation-resistant hepatocellular carcinoma cells and that targeting Raf-1 with sorafenib may resensitize these cells to radiation in vitro. Based on these studies, we hypothesize that the intensity of radiation-induced cell death can be strengthened with the use of sorafenib, which led to a partial response with liquefactive changes in our patient. Nevertheless, additional studies are required to confirm this hypothesis.
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